What is the recommended treatment approach for an adult with type 2 diabetes, including lifestyle modifications, first‑line metformin dosing, criteria for adding second‑line agents (SGLT2 inhibitor, GLP‑1 receptor agonist, DPP‑4 inhibitor, sulfonylurea), when to initiate insulin, and monitoring recommendations?

Treatment for Type 2 Diabetes in Adults

Start metformin 500–850 mg once or twice daily at diagnosis alongside lifestyle modifications, titrate to 2000 mg daily (1000 mg twice daily), then add an SGLT2 inhibitor when eGFR ≥30 mL/min/1.73 m² for cardiovascular and renal protection, followed by a GLP‑1 receptor agonist if HbA1c remains >7% after 3 months. 1, 2

Lifestyle Modifications (Foundation for All Patients)

• Prescribe ≥150 minutes per week of moderate‑intensity aerobic activity (e.g., brisk walking) plus resistance training on ≥2 non‑consecutive days per week to improve insulin sensitivity and cardiovascular health. 1, 2
• Target 5–10% weight loss from baseline through a plant‑forward diet emphasizing vegetables, fruits, whole grains, legumes, unsaturated fats, and nuts while limiting processed meats, refined carbohydrates, and sweetened beverages. 1, 2
• Restrict sodium intake to <2 g/day (approximately 5 g sodium chloride) to support blood‑pressure control. 1, 2
• Interrupt prolonged sitting every 30 minutes with brief standing or walking to reduce glycemic excursions. 2

First‑Line Pharmacotherapy: Metformin

• Initiate metformin 500 mg once or twice daily with meals at diagnosis, increasing by 500 mg weekly to a target of 2000 mg daily (1000 mg twice daily) for maximal glucose‑lowering efficacy. 1, 2
• Continue metformin indefinitely unless eGFR falls below 30 mL/min/1.73 m²; it reduces cardiovascular mortality, is weight‑neutral, and carries minimal hypoglycemia risk. 1, 2
• Use extended‑release formulations (e.g., 1000 mg once daily at dinner) if gastrointestinal side effects limit adherence to immediate‑release tablets. 2
• Monitor vitamin B12 levels periodically (annually or when anemia/peripheral neuropathy develops) because long‑term metformin can cause biochemical deficiency. 2

Second‑Line Therapy: SGLT2 Inhibitor

Add an SGLT2 inhibitor (empagliflozin 10–25 mg daily, dapagliflozin 10 mg daily, or canagliflozin 100–300 mg daily) to metformin when eGFR ≥30 mL/min/1.73 m², regardless of current HbA1c, to reduce CKD progression by 24–39%, lower heart‑failure hospitalizations, and decrease cardiovascular and all‑cause mortality. 1, 2

When to Prioritize SGLT2 Inhibitors

• Heart failure (HF) or chronic kidney disease (CKD): SGLT2 inhibitors are the preferred second agent because they reduce HF hospitalizations by 31% and slow kidney‑function decline independent of glucose lowering. 1, 2
• Hypertension or need for blood‑pressure reduction: SGLT2 inhibitors lower systolic blood pressure by 3–5 mmHg without increasing hypoglycemia risk. 2, 3
• Continue SGLT2 inhibitors even if eGFR falls below 30 mL/min/1.73 m² after initiation, because cardiovascular and renal protection persists despite reduced glycemic efficacy. 1, 2, 3

SGLT2 Inhibitor Safety Monitoring

• Expect a transient eGFR dip of 3–5 mL/min/1.73 m² within the first 2–4 weeks; this hemodynamic change is benign and reversible—do not discontinue the drug. 3
• Stop SGLT2 inhibitors 3 days before elective invasive procedures (4 days for ertugliflozin) to reduce euglycemic diabetic ketoacidosis risk; resume after the patient is stable. 3
• Educate patients to stop the drug and seek urgent care if they develop nausea, vomiting, abdominal pain, or dyspnea (signs of euglycemic DKA), even when glucose is not markedly elevated. 2, 3

Third‑Line Therapy: GLP‑1 Receptor Agonist

If HbA1c remains >7% after 3 months on metformin plus SGLT2 inhibitor, add a long‑acting GLP‑1 receptor agonist (semaglutide 0.5–2.0 mg weekly, dulaglutide 1.5 mg weekly, or liraglutide 1.2–1.8 mg daily) to achieve an additional 0.6–0.8% HbA1c reduction, 2–5 kg weight loss, and proven cardiovascular benefit. 1, 2

When to Prioritize GLP‑1 Receptor Agonists

• Established atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk: GLP‑1 receptor agonists reduce major adverse cardiovascular events by 26–29%, stroke risk, and cardiovascular death. 2
• Need for weight loss: GLP‑1 receptor agonists promote 2–5 kg weight loss (semaglutide up to 5–7 kg at 2.0 mg weekly), contrasting with weight gain from insulin or sulfonylureas. 2
• Minimal hypoglycemia risk: When not combined with sulfonylureas or insulin, GLP‑1 receptor agonists carry very low hypoglycemia risk. 2

GLP‑1 Receptor Agonist Dosing

Agent	Starting Dose	Titration Schedule	Target Dose
Semaglutide (weekly)	0.25 mg subcutaneously	Increase to 0.5 mg after 4 weeks, then 1.0 mg, then 2.0 mg if needed	1.0–2.0 mg weekly
Dulaglutide (weekly)	0.75 mg subcutaneously	Increase to 1.5 mg after 4 weeks	1.5 mg weekly
Liraglutide (daily)	0.6 mg subcutaneously	Increase to 1.2 mg after 1 week, then 1.8 mg if needed	1.2–1.8 mg daily

2

• Monitor for gastrointestinal side effects (nausea, vomiting, diarrhea) during the first 4–8 weeks after initiation or dose escalation; these typically resolve with continued use. 2

Alternative Second‑ or Third‑Line Agents

DPP‑4 Inhibitors (When GLP‑1 Receptor Agonists Are Unsuitable)

• Use DPP‑4 inhibitors (sitagliptin 100 mg daily, linagliptin 5 mg daily) when GLP‑1 receptor agonists are not tolerated or unavailable, recognizing they provide only modest HbA1c reduction (0.5–0.8%) and lack proven cardiovascular mortality benefit. 1, 2, 4, 5
• DPP‑4 inhibitors are weight‑neutral, carry minimal hypoglycemia risk, and can be used in renal impairment (linagliptin requires no dose adjustment; sitagliptin requires dose reduction when eGFR <45 mL/min/1.73 m²). 5, 6
• Never combine DPP‑4 inhibitors with GLP‑1 receptor agonists because they share the same incretin pathway and provide no additive benefit. 2, 5

Sulfonylureas (Avoid in Older Adults and High Hypoglycemia Risk)

• Avoid sulfonylureas (glipizide, glyburide, glimepiride) in patients ≥65 years, those with renal impairment, or those at high hypoglycemia risk because they increase severe hypoglycemia risk 7‑fold compared with metformin and are associated with 2‑fold higher all‑cause mortality. 2
• If sulfonylureas are required due to cost constraints, select agents with lower hypoglycemia potential (glipizide or glimepiride) and use the minimal effective dose; avoid glyburide entirely. 2

Thiazolidinediones (Selective Use Only)

• Consider pioglitazone only in selected cases when other agents are unsuitable, recognizing risks of weight gain (2–4 kg), fluid retention, and potential heart‑failure exacerbation. 1, 2

Insulin Initiation Criteria

Start basal insulin (NPH or long‑acting analog such as glargine or degludec) at 10 units once daily at bedtime (or 0.1–0.2 U/kg body weight) when HbA1c ≥10% or plasma glucose ≥300 mg/dL with symptomatic or catabolic presentation to prevent metabolic decompensation and preserve β‑cell function. 1, 2

Insulin Titration Protocol

• Increase basal insulin by 2–4 units every 3 days until fasting glucose reaches 80–130 mg/dL (4.4–7.2 mmol/L) without hypoglycemia. 1, 2
• Continue metformin and SGLT2 inhibitor or GLP‑1 receptor agonist when adding insulin to preserve cardiovascular and renal protection and reduce insulin requirements. 2
• If HbA1c remains >7% after 3–6 months despite optimized basal insulin, add prandial rapid‑acting insulin (4 units before the largest meal or 10% of basal dose) and titrate by 1–2 units every 3 days based on 2‑hour post‑prandial glucose. 1, 2

Hypoglycemia Management

• If hypoglycemia occurs, identify the cause and reduce the corresponding insulin dose by 10–20% immediately. 2
• Discontinue sulfonylureas when initiating insulin to avoid severe hypoglycemia, especially in older adults. 2

Glycemic Targets

• Target HbA1c 7.0–8.0% for most adults to balance efficacy with hypoglycemia risk. 1, 2
• Consider a more stringent target <6.5% for younger patients with short disease duration, long life expectancy, and no significant cardiovascular disease, provided hypoglycemia risk is low. 2
• Adopt a less stringent target of 7.5–8.5% for older adults (≥65–70 years), those with limited life expectancy (<10 years), history of severe hypoglycemia, advanced complications, or extensive comorbidities. 1, 2

Monitoring Recommendations

• Measure HbA1c every 3 months until target is reached, then continue quarterly monitoring. 1, 2
• Do not postpone therapeutic intensification beyond 3 months of inadequate control; treatment inertia increases microvascular complication risk. 2
• Check eGFR at baseline and at least annually to ensure continued safety of metformin and SGLT2 inhibitors; increase monitoring frequency to every 3–6 months if eGFR declines toward 45 mL/min/1.73 m². 2
• Individualize home self‑monitoring of blood glucose based on the pharmacologic regimen (e.g., more frequent monitoring with insulin, less frequent with metformin alone). 2

Adjunctive Cardiovascular Risk Management

• Prescribe moderate‑to‑high intensity statin therapy for all adults aged 40–75 years with diabetes, independent of baseline LDL or calculated cardiovascular risk. 2
• Target blood pressure <130/80 mmHg using renin‑angiotensin system inhibitors (ACE inhibitors or ARBs) as first‑line agents in patients with hypertension and albuminuria. 1, 2
• Recommend low‑dose aspirin (75–162 mg daily) for secondary prevention in patients with established ASCVD, unless contraindicated. 2

Common Pitfalls to Avoid

• Never discontinue metformin when adding other agents (SGLT2 inhibitors, GLP‑1 receptor agonists, or insulin) unless contraindicated; it remains foundational therapy throughout intensification. 2
• Do not delay insulin initiation in patients with HbA1c ≥10% or symptomatic hyperglycemia; early combination therapy is required to achieve control. 2
• Avoid combining DPP‑4 inhibitors with GLP‑1 receptor agonists; they share the same mechanism and provide no additive benefit. 2, 5
• Do not continue sulfonylureas when adding insulin or GLP‑1 receptor agonists; this markedly raises severe hypoglycemia risk, especially in older adults. 2
• Do not discontinue SGLT2 inhibitors solely because of the expected early eGFR dip (3–5 mL/min/1.73 m²); this hemodynamic change is benign and reversible. 3
• Avoid therapeutic inertia: intensify therapy within 3 months if HbA1c remains above target, as delays prolong hyperglycemia exposure and increase complication risk. 2